Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs

Abstract Background Diuretic braking during furosemide continuous rate infusion (FCRI) curtails urine production. Hypothesis Renin‐angiotensin‐aldosterone system (RAAS) activation mediates braking, and RAAS inhibition will increase urine production. Animals Ten healthy purpose‐bred male dogs. Method...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Darcy Adin, Clarke Atkins, Gabrielle Wallace, Allison Klein
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	aldosterone antagonist angiotensin‐converting enzyme inhibitor continuous rate infusion diuretic resistance neurohormone urine production Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/789a23e51ed64ded8d8076212e8a2245
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:789a23e51ed64ded8d8076212e8a2245
record_format	dspace
spelling	oai:doaj.org-article:789a23e51ed64ded8d8076212e8a22452021-11-30T17:01:02ZEffect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs1939-16760891-664010.1111/jvim.16097https://doaj.org/article/789a23e51ed64ded8d8076212e8a22452021-05-01T00:00:00Zhttps://doi.org/10.1111/jvim.16097https://doaj.org/toc/0891-6640https://doaj.org/toc/1939-1676Abstract Background Diuretic braking during furosemide continuous rate infusion (FCRI) curtails urine production. Hypothesis Renin‐angiotensin‐aldosterone system (RAAS) activation mediates braking, and RAAS inhibition will increase urine production. Animals Ten healthy purpose‐bred male dogs. Methods Dogs received placebo, benazepril, or benazepril and spironolactone PO for 3 days before a 5‐hour FCRI (0.66 mg/kg/h) in a 3‐way, randomized, blinded, cross‐over design. Body weight (BW), serum creatinine concentration (sCr), serum electrolyte concentrations, PCV, and total protein concentration were measured before PO medications, at hours 0 and 5 of FCRI, and at hour 24. During the FCRI, water intake, urine output, urine creatinine concentration, and urine electrolyte concentrations were measured hourly. Selected RAAS components were measured before and after FCRI. Variables were compared among time points and treatments. Results Diuretic braking and urine production were not different among treatments. Loss of BW, hemoconcentration, and decreased serum chloride concentration occurred during FCRI with incomplete recovery at hour 24 for all treatments. Although unchanged during FCRI, sCr increased and serum sodium concentration decreased at hour 24 for all treatments. Plasma aldosterone and angiotensin‐II concentrations increased significantly at hour 5 for all treatments, despite suppressed angiotensin‐converting enzyme activity during benazepril background treatment. Conclusions The neurohormonal profile during FCRI supports RAAS mediation of diuretic braking in this model. Background treatment with benazepril with or without spironolactone did not mitigate braking, but was well tolerated. Delayed changes in sCr and serum sodium concentration and incomplete recovery of hydration indicators caused by furosemide hold implications for clinical patients.Darcy AdinClarke AtkinsGabrielle WallaceAllison KleinWileyarticlealdosterone antagonistangiotensin‐converting enzyme inhibitorcontinuous rate infusiondiuretic resistanceneurohormoneurine productionVeterinary medicineSF600-1100ENJournal of Veterinary Internal Medicine, Vol 35, Iss 3, Pp 1245-1254 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	aldosterone antagonist angiotensin‐converting enzyme inhibitor continuous rate infusion diuretic resistance neurohormone urine production Veterinary medicine SF600-1100
spellingShingle	aldosterone antagonist angiotensin‐converting enzyme inhibitor continuous rate infusion diuretic resistance neurohormone urine production Veterinary medicine SF600-1100 Darcy Adin Clarke Atkins Gabrielle Wallace Allison Klein Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
description	Abstract Background Diuretic braking during furosemide continuous rate infusion (FCRI) curtails urine production. Hypothesis Renin‐angiotensin‐aldosterone system (RAAS) activation mediates braking, and RAAS inhibition will increase urine production. Animals Ten healthy purpose‐bred male dogs. Methods Dogs received placebo, benazepril, or benazepril and spironolactone PO for 3 days before a 5‐hour FCRI (0.66 mg/kg/h) in a 3‐way, randomized, blinded, cross‐over design. Body weight (BW), serum creatinine concentration (sCr), serum electrolyte concentrations, PCV, and total protein concentration were measured before PO medications, at hours 0 and 5 of FCRI, and at hour 24. During the FCRI, water intake, urine output, urine creatinine concentration, and urine electrolyte concentrations were measured hourly. Selected RAAS components were measured before and after FCRI. Variables were compared among time points and treatments. Results Diuretic braking and urine production were not different among treatments. Loss of BW, hemoconcentration, and decreased serum chloride concentration occurred during FCRI with incomplete recovery at hour 24 for all treatments. Although unchanged during FCRI, sCr increased and serum sodium concentration decreased at hour 24 for all treatments. Plasma aldosterone and angiotensin‐II concentrations increased significantly at hour 5 for all treatments, despite suppressed angiotensin‐converting enzyme activity during benazepril background treatment. Conclusions The neurohormonal profile during FCRI supports RAAS mediation of diuretic braking in this model. Background treatment with benazepril with or without spironolactone did not mitigate braking, but was well tolerated. Delayed changes in sCr and serum sodium concentration and incomplete recovery of hydration indicators caused by furosemide hold implications for clinical patients.
format	article
author	Darcy Adin Clarke Atkins Gabrielle Wallace Allison Klein
author_facet	Darcy Adin Clarke Atkins Gabrielle Wallace Allison Klein
author_sort	Darcy Adin
title	Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
title_short	Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
title_full	Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
title_fullStr	Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
title_full_unstemmed	Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
title_sort	effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/789a23e51ed64ded8d8076212e8a2245
work_keys_str_mv	AT darcyadin effectofspironolactoneandbenazeprilonfurosemideinduceddiuresisandreninangiotensinaldosteronesystemactivationinnormaldogs AT clarkeatkins effectofspironolactoneandbenazeprilonfurosemideinduceddiuresisandreninangiotensinaldosteronesystemactivationinnormaldogs AT gabriellewallace effectofspironolactoneandbenazeprilonfurosemideinduceddiuresisandreninangiotensinaldosteronesystemactivationinnormaldogs AT allisonklein effectofspironolactoneandbenazeprilonfurosemideinduceddiuresisandreninangiotensinaldosteronesystemactivationinnormaldogs
_version_	1718406452337442816

Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs

Ejemplares similares